These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8004315)

  • 1. Pulmonary function abnormalities in thalassemia major and the role of iron overload.
    Factor JM; Pottipati SR; Rappoport I; Rosner IK; Lesser ML; Giardina PJ
    Am J Respir Crit Care Med; 1994 Jun; 149(6):1570-4. PubMed ID: 8004315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary Functions in Children With Thalassemia Major.
    Ozyoruk D; Misirlioglu ED
    J Pediatr Hematol Oncol; 2015 Nov; 37(8):605-10. PubMed ID: 26422288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-thalassemia and pulmonary function.
    Piatti G; Allegra L; Ambrosetti U; Cappellini MD; Turati F; Fiorelli G
    Haematologica; 1999 Sep; 84(9):804-8. PubMed ID: 10477453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-thalassemia major: thin-section CT features and correlation with pulmonary function and iron overload.
    Khong PL; Chan GC; Lee SL; Au WY; Fong DY; Tsang KW; Ooi GC
    Radiology; 2003 Nov; 229(2):507-12. PubMed ID: 14595151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM; Griffith PM; Nienhuis AW; McLaren CE; Young NS; Tucker EE; Allen CJ; Farrell DE; Harris JW
    N Engl J Med; 1994 Sep; 331(9):567-73. PubMed ID: 8047080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
    Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
    Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary function test in transfusion-dependent β-thalassemia major patients: a pilot study.
    Alyasin S; Moghtaderi M; Amin R; Kashef S; Karimi M
    Pediatr Hematol Oncol; 2011 May; 28(4):329-33. PubMed ID: 21345079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary dysfunction in transfusion-dependent patients with thalassemia major.
    Carnelli V; D'Angelo E; Pecchiari M; Ligorio M; D'Angelo E
    Am J Respir Crit Care Med; 2003 Jul; 168(2):180-4. PubMed ID: 12738605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined iron chelation therapy.
    Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lungs in thalassaemia major patients receiving regular transfusion.
    Tai DY; Wang YT; Lou J; Wang WY; Mak KH; Cheng HK
    Eur Respir J; 1996 Jul; 9(7):1389-94. PubMed ID: 8836648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.